Gadolinium-based contrast agents and nephrogenic systemic fibrosis.
Vitti
Richard A
RA
D000046:Academic Medical Centers / Q000706:statistics & numerical data*; D000293:Adolescent; D000328:Adult; D000368:Aged; D002614:Chelating Agents; D015897:Comorbidity; D005682:Gadolinium; D006801:Humans; D015994:Incidence; D008279:Magnetic Resonance Imaging / Q000706:statistics & numerical data*; D008875:Middle Aged; D051437:Renal Insufficiency / Q000453:epidemiology*; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012595:Scleroderma, Systemic / Q000453:epidemiology*; D013577:Syndrome; D014481:United States / Q000453:epidemiology
D002614:Chelating Agents; D005682:Gadolinium